PMID- 20363096
OWN - NLM
STAT- MEDLINE
DCOM- 20100917
LR  - 20220408
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 64
IP  - 6
DP  - 2010 Jul
TI  - Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung 
      cancer is related to clinicopathologic characteristics or patient prognosis.
PG  - 399-408
LID - 10.1016/j.biopha.2010.01.018 [doi]
AB  - CONTEXT: MicroRNAs (miRNAs) represent a class of small non-coding RNAs that 
      regulate the gene expressions at the posttranscriptional level, subsequently 
      control crucial physiological processes. Recent evidence demonstrates that some 
      miRNAs have the functions similar to oncogene or tumor suppressors, it may play 
      important roles in tumorigenesis. MiRNA expression profiles may become useful 
      biomarkers for cancer diagnostics, prognosis and prediction of response to 
      treatment, and it could be a powerful tool for cancer prevention and 
      therapeutics. OBJECTIVE: To explore the global expression profile of miRNAs in 
      non small cell lung cancer (NSCLC) and its potential relevance to 
      clinicopathological characteristics and prognosis. METHODS: LNA microRNA 
      microarrays were utilized to detect miRNA expression levels in eight surgically 
      removed lung carcinoma tissues (LCT) and their corresponding normal lung tissues 
      (NT). After initial microarray validation by quantitative real-time reverse 
      transcription polymerase chain reaction assays (qRT-PCR), miR-21, miR-143 and 
      miR-181a were selected for further study in another 47 paired LCTs and matched 
      NTs by qRT-PCR using Taqman microRNA assay. RESULTS: Twenty-seven microRNAs were 
      observed to be deregulated greater than two-fold in LCT compared with NT by 
      microarray. Consistenting with the microarray, the expression level of miR-21 by 
      qRT-PCR was significantly higher in tumor tissues than in adjacent normal tissues 
      (P=0.026); while miR-143 (P=0.000) and miR-181a (P=0.000) were downregulated in 
      LCT. Interestingly, among the 47 NSCLC cases, low level expression of miR-143 was 
      significantly correlated with smoking status (P=0.026), high miR-21 expression 
      (hazard ratio, 5.993; 95% confidence interval, 2.518-14.264; P=0.000) and low 
      miR-181a expression (hazard ratio, 0.328; 95% confidence interval 0.142-0.756; 
      P=0.009) were associated with poor survival, independent of clinical covariates, 
      including TNM staging, lymph note status. CONCLUSION: Our data thus indicating 
      the potential of miR-21, miR-143 and miR-181a as a novel diagnostic or prognostic 
      biomarker for NSCLC. Besides, these data will guide further studies of specific 
      microRNAs might become potential targets for therapeutic intervention.
CI  - Copyright 2010 Elsevier Masson SAS. All rights reserved.
FAU - Gao, Wen
AU  - Gao W
AD  - Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 
      Nanjing, China, 210029.
FAU - Yu, Yue
AU  - Yu Y
FAU - Cao, Hailong
AU  - Cao H
FAU - Shen, Hua
AU  - Shen H
FAU - Li, Xiaodong
AU  - Li X
FAU - Pan, Shiyang
AU  - Pan S
FAU - Shu, Yongqian
AU  - Shu Y
LA  - eng
PT  - Journal Article
DEP - 20100225
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (MIRN143 microRNA, human)
RN  - 0 (MIRN21 microRNA, human)
RN  - 0 (MIrn181 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Base Sequence
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/mortality/pathology
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation
MH  - Humans
MH  - Lung Neoplasms/*genetics/mortality/pathology
MH  - MicroRNAs/*analysis
MH  - Molecular Sequence Data
MH  - Oligonucleotide Array Sequence Analysis
MH  - Prognosis
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2010/04/07 06:00
MHDA- 2010/09/21 06:00
CRDT- 2010/04/06 06:00
PHST- 2009/11/18 00:00 [received]
PHST- 2010/01/29 00:00 [accepted]
PHST- 2010/04/06 06:00 [entrez]
PHST- 2010/04/07 06:00 [pubmed]
PHST- 2010/09/21 06:00 [medline]
AID - S0753-3322(10)00045-4 [pii]
AID - 10.1016/j.biopha.2010.01.018 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2010 Jul;64(6):399-408. doi: 10.1016/j.biopha.2010.01.018. 
      Epub 2010 Feb 25.